DE69940157D1 - Anthrax-impfstoff - Google Patents

Anthrax-impfstoff

Info

Publication number
DE69940157D1
DE69940157D1 DE69940157T DE69940157T DE69940157D1 DE 69940157 D1 DE69940157 D1 DE 69940157D1 DE 69940157 T DE69940157 T DE 69940157T DE 69940157 T DE69940157 T DE 69940157T DE 69940157 D1 DE69940157 D1 DE 69940157D1
Authority
DE
Germany
Prior art keywords
impfstoff
anthrax
aureus
intoxication
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69940157T
Other languages
English (en)
Inventor
John S Lee
Peter Pushko
Michael D Parker
Jonathan F Smith
Susan L Welkos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
U S MEDICAL RES INST OF INFECT
US Medical Research Institute of Infectious Diseases
Original Assignee
U S MEDICAL RES INST OF INFECT
US Medical Research Institute of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S MEDICAL RES INST OF INFECT, US Medical Research Institute of Infectious Diseases filed Critical U S MEDICAL RES INST OF INFECT
Application granted granted Critical
Publication of DE69940157D1 publication Critical patent/DE69940157D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DE69940157T 1998-07-10 1999-07-09 Anthrax-impfstoff Expired - Fee Related DE69940157D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9241698P 1998-07-10 1998-07-10
PCT/US1999/015568 WO2000002522A2 (en) 1998-07-10 1999-07-09 Anthrax vaccine

Publications (1)

Publication Number Publication Date
DE69940157D1 true DE69940157D1 (en) 2009-02-05

Family

ID=22233100

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69940157T Expired - Fee Related DE69940157D1 (en) 1998-07-10 1999-07-09 Anthrax-impfstoff
DE69941454T Expired - Fee Related DE69941454D1 (de) 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69941454T Expired - Fee Related DE69941454D1 (de) 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung

Country Status (7)

Country Link
US (2) US6632640B1 (de)
EP (2) EP1097213B1 (de)
AT (2) ATE418612T1 (de)
AU (2) AU758019B2 (de)
CA (2) CA2337966A1 (de)
DE (2) DE69940157D1 (de)
WO (2) WO2000002522A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
CA2337966A1 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Vaccine against staphylococcus intoxication
EP1105154B1 (de) * 1998-08-13 2016-06-01 Walter Reed Army Institute of Research Impfstoffe gegen bakterielle superantigene
CA2366900A1 (en) 1999-04-16 2000-10-26 Stephen J. Wisniewski Drug delivery device comprising a dual chamber reservoir
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
RU2287581C2 (ru) 2001-12-05 2006-11-20 Ракеш БХАТНАГАР Способ получения нетоксичной противосибиреязвенной вакцины
AU2003224265A1 (en) * 2002-04-11 2003-10-27 Powderject Research Limited Nucleic acid immunization
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
EP1575505A4 (de) * 2002-09-10 2007-01-24 Vical Inc Codon-optimierte vakzine auf polynucleotid-basis gegen infektionen mit bacillus anthracis
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
JP4991108B2 (ja) * 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
EP1608762B1 (de) * 2003-03-20 2014-01-08 Alphavax, Inc. Verbesserte alphavirus replikons und helferkonstrukt
WO2005034841A2 (en) * 2003-05-14 2005-04-21 Merck & Co., Inc. Anthrax vaccine
AU2004257214B2 (en) * 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
EP1670505B1 (de) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna-promotor und anthrax-vakzine
WO2005086637A2 (en) 2004-02-11 2005-09-22 Ligocyte Pharmaceuticals, Inc. Anthrax antigens and methods of use
KR101505496B1 (ko) 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
BRPI0609362A2 (pt) * 2005-04-11 2010-03-30 Us Gov Health & Human Serv vetor de adenovìrus recombinante, adenovìrus recombinante, composição imunogênica e método para a produção da referida composição imunogênica
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
US20070248960A1 (en) * 2006-04-19 2007-10-25 Rees Dianne M Arrays containing cleavable RNAi molecules
CA2689588C (en) 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
CN101951948B (zh) 2007-08-31 2015-12-09 芝加哥大学 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009063507A1 (en) * 2007-11-12 2009-05-22 Rakesh Bhatnagar Dna vaccine against anthrax
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
BRPI0920041A2 (pt) 2008-10-06 2017-06-27 Univ Chicago composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
EP3281947B1 (de) 2009-04-03 2020-02-12 The University of Chicago Zusammensetzungen und verfahren in verbindung mit protein-a (spa)-varianten
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
SG186290A1 (en) 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (de) 2010-09-09 2013-07-17 The University of Chicago Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen
WO2012170097A2 (en) * 2011-03-16 2012-12-13 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2744517B1 (de) 2011-08-15 2019-03-13 The University of Chicago Zusammensetzungen und verfahren in zusammenhang mit antikörpern gegen das staphylokokken-protein a
US9968668B2 (en) 2012-04-26 2018-05-15 The University Of Chicago Staphylococcal coagulase antigens and methods of their use
CN104703622B (zh) 2012-04-26 2017-05-24 芝加哥大学 与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法
JP6632974B2 (ja) * 2013-06-19 2020-01-22 インテグレイテッド バイオセラピューティクス，インコーポレイテッド フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物
CA3010678A1 (en) 2016-01-10 2017-07-20 Neotx Therapeutics Ltd. Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
US11505722B2 (en) * 2017-06-30 2022-11-22 The Boeing Company Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials
MX2020001046A (es) 2017-07-27 2020-08-06 Integrated Biotherapeutic Vaccines Inc Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.
EP3969043A1 (de) 2019-05-15 2022-03-23 Neotx Therapeutics Ltd. Krebsbehandlung
CN115151559A (zh) 2019-10-02 2022-10-04 扬森疫苗与预防公司 葡萄球菌肽和使用方法
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014634A1 (en) * 1992-01-28 1993-08-05 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69430369T2 (de) * 1993-09-15 2002-10-17 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanter alphavirus vektor
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
GB9604045D0 (en) * 1996-02-26 1996-04-24 Smithkline Beecham Plc Novel compounds
GB9618107D0 (en) * 1996-08-30 1996-10-09 Secr Defence Vaccine production
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
JP4422330B2 (ja) * 1998-02-15 2010-02-24 財団法人化学及血清療法研究所 新規な免疫異常性疾患予防・治療用剤
WO2000000616A2 (en) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
CA2337966A1 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Vaccine against staphylococcus intoxication
EP1105154B1 (de) * 1998-08-13 2016-06-01 Walter Reed Army Institute of Research Impfstoffe gegen bakterielle superantigene
CA2354374A1 (en) * 1998-12-07 2000-06-15 U.S. Medical Research Institute Of Infectious Diseases Live attenuated venezuelan equine encephalitis vaccine

Also Published As

Publication number Publication date
DE69941454D1 (de) 2009-11-05
ATE443768T1 (de) 2009-10-15
AU5667399A (en) 2000-02-01
AU5542699A (en) 2000-02-01
WO2000002523A2 (en) 2000-01-20
CA2339355A1 (en) 2000-01-20
WO2000002523A9 (en) 2000-07-27
US20040009183A1 (en) 2004-01-15
ATE418612T1 (de) 2009-01-15
US7374931B2 (en) 2008-05-20
EP1097212A2 (de) 2001-05-09
EP1097213B1 (de) 2009-09-23
EP1097213A2 (de) 2001-05-09
WO2000002523A3 (en) 2000-11-23
WO2000002522A2 (en) 2000-01-20
US6632640B1 (en) 2003-10-14
EP1097212B1 (de) 2008-12-24
AU761021B2 (en) 2003-05-29
AU758019B2 (en) 2003-03-13
WO2000002522A9 (en) 2001-04-05
WO2000002522A3 (en) 2000-10-12
CA2337966A1 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
DE69940157D1 (en) Anthrax-impfstoff
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
EP2196472A3 (de) Zusammensetzungen und Verfahren zur Auslösung einer Immunantwort auf Basis Alphavirus-Vektoren-Systeme
TR200806259T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
HK1080506A1 (en) Fusion proteins of mycobacterium tuberculosis
ZA975211B (en) Compositions and methods for administering borrelia DNA.
WO2002007742A8 (en) Bacteriophage having multiple host range
EA200100565A1 (ru) Новые стрептококковые антигены
WO2000002524A3 (en) Botulinum neurotoxin vaccine
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
AU2001249380A1 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
WO2005009378A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
AU2001232513A1 (en) An industrial robot with an actuated brake system, which cooperate with the robot's control system
AU2002218383A1 (en) Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant
AU2001251162A1 (en) Hair conditioning composition comprising vinylpyrrolidone copolymer
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002011549A3 (en) Treatment of mycobacterial infection
MX9802809A (es) Ureasa para el tratamiento de infecciones de helicobacter pylori.
AU2469202A (en) Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau r4
WO1997041252A3 (en) Dna, rna and a protein useful for detection of a mycobacterial infection
AU2003264681A8 (en) Serological diagnostic method
AUPR001300A0 (en) Caged animal environment enrichment device
AU2002224692A1 (en) Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein STAAU_R4

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee